Curevac starts phase 1 clinical study of modified, omicron-targeting covid-19 vaccine candidate

Phase 1 dose-escalation study to be conducted at clinical sites in the u.s., the uk, australia, and the philippines milestone demonstrates curevac's continued execution on comprehensive clinical program of second-generation vaccine candidates for infectious diseases tÜbingen, germany and boston, ma / accesswire / august 18, 2022 / curevac n.v. (nasdaq:cvac), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced the start of a phase 1 study of the modified covid-19 mrna vaccine candidate cv0501, administered as a booster dose to previous covid-19 vaccination.
CVAC Ratings Summary
CVAC Quant Ranking